CLDX - Celldex Therapeutics Inc.
IEX Last Trade
41.35
1.420 3.434%
Share volume: 700,623
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$39.93
1.42
3.56%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-09 | 2023-02-28 | 2023-05-04 | 2023-08-08 | 2023-11-02 | 2024-02-26 | 2024-05-06 | |
| Assets | |||||||||
| Total Assets | 402.961 M | 369.226 M | 352.735 M | 324.519 M | 299.311 M | 280.256 M | 465.627 M | 868.847 M | |
| Current Assets | 367.979 M | 334.599 M | 317.693 M | 289.597 M | 264.820 M | 245.933 M | 431.693 M | 835.324 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 11.065 M | 10.939 M | 12.394 M | 9.896 M | 12.005 M | 10.333 M | 5.467 M | 8.807 M | |
| Short Term Investments | 11.065 M | 10.939 M | 12.394 M | 9.896 M | 12.005 M | 10.333 M | 5.467 M | 8.807 M | |
| Total Receivables | 97.000 K | 189.000 K | 347.000 K | 1.314 M | 118.000 K | 252.000 K | 2.628 M | 2.671 M | |
| Current Cash | 356.817 M | 323.471 M | 304.952 M | 278.387 M | 252.697 M | 235.348 M | 423.598 M | 823.846 M | |
| Total Non-current Assets | 34.982 M | 34.627 M | 35.042 M | 34.922 M | 34.491 M | 34.323 M | 33.934 M | 33.523 M | |
| Property Plant Equipment | 3.744 M | 3.753 M | 3.747 M | 3.995 M | 3.938 M | 4.162 M | 4.060 M | 4.061 M | |
| Other Assets | 104.000 K | 104.000 K | 104.000 K | 104.000 K | 107.000 K | 107.000 K | 107.000 K | 107.000 K | |
| Intangible Assets | 27.190 M | 27.190 M | 27.190 M | 27.190 M | 27.190 M | 27.190 M | 27.190 M | 27.190 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 402.961 M | 369.226 M | 352.735 M | 324.519 M | 299.311 M | 280.256 M | 465.627 M | 868.847 M | |
| Total liabilities | 37.868 M | 23.810 M | 26.531 M | 21.779 M | 21.774 M | 33.538 M | 36.456 M | 30.234 M | |
| Total current liabilities | 29.949 M | 16.287 M | 18.610 M | 15.219 M | 15.646 M | 27.836 M | 31.125 M | 26.291 M | |
| Accounts Payable | 902.000 K | 2.272 M | 3.340 M | 3.374 M | 881.000 K | 3.586 M | 3.494 M | 3.234 M | |
| Other liabilities | 3.720 M | 3.720 M | 3.720 M | 2.790 M | 2.790 M | 2.790 M | 2.790 M | 1.860 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 3.720 M | 3.720 M | 3.720 M | 2.790 M | 2.790 M | 2.790 M | 2.790 M | 1.860 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 365.093 M | 345.416 M | 326.204 M | 302.740 M | 277.537 M | 246.718 M | 429.171 M | 838.613 M | |
| Common stock | 46.759 M | 46.916 M | 47.138 M | 47.214 M | 47.253 M | 47.261 M | 52.068 M | 58.871 M | |
| Retained earnings | -1.203 B | -1.229 B | -1.256 B | -1.285 B | -1.316 B | -1.354 B | -1.397 B | -1.430 B |